Coldstream Capital Management Inc. Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Coldstream Capital Management Inc. purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) during the 4th quarter, Holdings Channel.com reports. The fund purchased 19,240 shares of the biopharmaceutical company’s stock, valued at approximately $1,652,000.

Several other large investors have also recently made changes to their positions in the business. BlackRock Inc. raised its stake in shares of Gilead Sciences by 1.2% during the third quarter. BlackRock Inc. now owns 128,460,733 shares of the biopharmaceutical company’s stock worth $7,924,739,000 after acquiring an additional 1,523,122 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Gilead Sciences by 1.5% in the third quarter. Vanguard Group Inc. now owns 112,087,271 shares of the biopharmaceutical company’s stock worth $6,914,663,000 after purchasing an additional 1,691,194 shares during the last quarter. State Street Corp grew its holdings in shares of Gilead Sciences by 2.2% in the third quarter. State Street Corp now owns 59,240,350 shares of the biopharmaceutical company’s stock worth $3,654,537,000 after purchasing an additional 1,293,414 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Gilead Sciences by 324.8% in the first quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after purchasing an additional 13,764,169 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Gilead Sciences by 70.6% in the first quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock worth $921,006,000 after purchasing an additional 6,410,047 shares during the last quarter. 78.72% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 6,126 shares of the company’s stock in a transaction that occurred on Monday, March 13th. The stock was sold at an average price of $78.99, for a total value of $483,892.74. Following the completion of the transaction, the insider now directly owns 70,130 shares in the company, valued at approximately $5,539,568.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Trading Down 3.2 %

Shares of NASDAQ:GILD opened at $77.31 on Friday. Gilead Sciences, Inc. has a 12-month low of $57.17 and a 12-month high of $89.74. The company has a current ratio of 1.29, a quick ratio of 1.15 and a debt-to-equity ratio of 1.14. The company has a market cap of $96.41 billion, a PE ratio of 21.18, a price-to-earnings-growth ratio of 0.95 and a beta of 0.38. The stock has a 50 day moving average of $83.20 and a 200 day moving average of $78.51.

Gilead Sciences (NASDAQ:GILD – Get Rating) last posted its quarterly earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.17. Gilead Sciences had a return on equity of 44.46% and a net margin of 16.83%. The business had revenue of $7.39 billion during the quarter, compared to the consensus estimate of $6.63 billion. During the same period in the prior year, the company posted $0.69 EPS. The firm’s revenue for the quarter was up 2.0% compared to the same quarter last year. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 6.86 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 30th. Shareholders of record on Wednesday, March 15th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 3.88%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.73. The ex-dividend date of this dividend is Tuesday, March 14th. Gilead Sciences’s dividend payout ratio is presently 82.19%.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Oppenheimer lifted their price target on shares of Gilead Sciences from $95.00 to $105.00 in a report on Thursday, December 1st. Cowen boosted their target price on shares of Gilead Sciences from $90.00 to $95.00 in a report on Friday, February 10th. Bank of America restated a “neutral” rating and set a $85.00 target price on shares of Gilead Sciences in a report on Tuesday, December 13th. StockNews.com assumed coverage on shares of Gilead Sciences in a report on Thursday. They set a “strong-buy” rating on the stock. Finally, Piper Sandler lifted their price target on Gilead Sciences from $111.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, February 3rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $89.40.

Gilead Sciences Profile

(Get Rating)

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.